Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Preclinical evidence suggests that a fasting mimicking diet (FMD) can make cancer cells more vulnerable to chemotherapy, while protecting normal cells. In this randomized phase II clinical trial of 131 patients with HER2 negative early stage breast cancer, the authors demonstrate that FMD is safe an...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stefanie de Groot, Rieneke T. Lugtenberg, Danielle Cohen, Marij J. P. Welters, Ilina Ehsan, Maaike P. G. Vreeswijk, Vincent T. H. B. M. Smit, Hiltje de Graaf, Joan B. Heijns, Johanneke E. A. Portielje, Agnes J. van de Wouw, Alex L. T. Imholz, Lonneke W. Kessels, Suzan Vrijaldenhoven, Arnold Baars, Elma Meershoek-Klein Kranenbarg, Marjolijn Duijm-de Carpentier, Hein Putter, Jacobus J. M. van der Hoeven, Johan W. R. Nortier, Valter D. Longo, Hanno Pijl, Judith R. Kroep, Dutch Breast Cancer Research Group (BOOG)
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2020
Materias:	Science Q
Acceso en línea:	https://doaj.org/article/ece7e746301b495eb80ac3a814697099
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Sea el primero en dejar un comentario!

Fasting mimicking diet as an adjunct to neoadjuvant chemotherapy for breast cancer in the multicentre randomized phase 2 DIRECT trial

Ejemplares similares